RLS-0071, a novel anti-inflammatory agent, significantly reduced inflammatory biomarkers in a randomised human evaluation of mechanisms and safety study.
Kenji CunnionJessica GossPamela HairLinda DellDestrey RobersonUlrich ThienelMeike MüllerSaskia Carstensen-AurèchePhilipp BadorrekOlaf HolzJens M HohlfeldPublished in: ERJ open research (2024)
This clinical trial demonstrated that RLS-0071 was safe and well tolerated and modulated neutrophil-mediated inflammation in humans after inhaled LPS challenge, consistent with results from prior animal model studies.